---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-024070"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2022-06-27T23:59:59+00:00"
generated_at: "2026-06-24T23:09:33.758588+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash

## Summary
- Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.
- Seller eligible for earn-out payment in 2024 of up to ~16% of NOK 3.175B based on growth targets.
- Kappa is a leading science-based manufacturer of specialty vitamin K2 for human nutrition.
- At Annual Meeting, shareholders elected three Class 1 directors, ratified RSM US LLP as auditor, and approved executive compensation on advisory basis.
- Acquisition financed through Balchem's existing revolving credit facility and cash on hand.

## SEC filing metadata
- accession: 0001140361-22-024070
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2022-06-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000114036122024070/0001140361-22-024070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000114036122024070/brhc10039086_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-024070
- JSON: https://secwatch.observer/filing/0001140361-22-024070.json
- Plain text: https://secwatch.observer/filing/0001140361-22-024070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.